Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

United Therapeutics (UTHR) Operating Expenses (2016 - 2026)

United Therapeutics' Operating Expenses history spans 17 years, with the latest figure at $433.5 million for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 14.62% to $433.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.7 billion, a 12.65% increase, with the full-year FY2025 number at $1.7 billion, up 12.65% from a year prior.
  • Operating Expenses hit $433.5 million in Q4 2025 for United Therapeutics, up from $411.0 million in the prior quarter.
  • Over the last five years, Operating Expenses for UTHR hit a ceiling of $443.9 million in Q1 2021 and a floor of $173.9 million in Q1 2022.
  • Historically, Operating Expenses has averaged $321.0 million across 5 years, with a median of $318.6 million in 2022.
  • Biggest five-year swings in Operating Expenses: surged 134.12% in 2021 and later crashed 60.82% in 2022.
  • Tracing UTHR's Operating Expenses over 5 years: stood at $245.4 million in 2021, then increased by 28.73% to $315.9 million in 2022, then increased by 12.25% to $354.6 million in 2023, then grew by 6.66% to $378.2 million in 2024, then grew by 14.62% to $433.5 million in 2025.
  • Business Quant data shows Operating Expenses for UTHR at $433.5 million in Q4 2025, $411.0 million in Q3 2025, and $434.1 million in Q2 2025.